TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
39.86
-0.34 (-0.85%)
At close: Mar 28, 2025, 4:00 PM
39.78
-0.08 (-0.20%)
After-hours: Mar 28, 2025, 7:56 PM EDT
TG Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for TG Therapeutics stock have an average target of 40.67, with a low estimate of 22 and a high estimate of 55. The average target predicts an increase of 2.03% from the current stock price of 39.86.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TG Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +37.98% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +37.98% | Jan 15, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $30 → $43 | Buy | Maintains | $30 → $43 | +7.88% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $55 | Strong Buy | Maintains | $49 → $55 | +37.98% | Nov 5, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $20 → $22 | Hold | Maintains | $20 → $22 | -44.81% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
571.55M
from 329.00M
Increased by 73.72%
Revenue Next Year
789.85M
from 571.55M
Increased by 38.19%
EPS This Year
0.89
from 0.15
Increased by 493.86%
EPS Next Year
1.83
from 0.89
Increased by 105.19%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 677.1M | 929.7M | 1.2B | ||
| Avg | 571.6M | 789.9M | 992.1M | ||
| Low | 517.2M | 637.0M | 803.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 105.8% | 62.7% | 50.8% | ||
| Avg | 73.7% | 38.2% | 25.6% | ||
| Low | 57.2% | 11.5% | 1.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.32 | 2.35 | 2.85 | ||
| Avg | 0.89 | 1.83 | 2.64 | ||
| Low | 0.44 | 0.95 | 2.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 782.0% | 164.0% | 55.7% | ||
| Avg | 493.9% | 105.2% | 44.3% | ||
| Low | 194.0% | 6.7% | 31.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.